Why screening for depressive symptoms in patients with arthritis is needed
Search results for: joint replacement
Rheumatologists on the Move
Awards, appointments and announcements in the world of rheumatology
Practicing Rheumatology in Dubai
Rheumatologist Humeira Badsha, MD, describes caring for rheumatology patients in the United Arab Emirates, launching the Emirates Arthritis Foundation
Why Farber Disease May Be Misdiagnosed as Juvenile Idiopathic Arthritis
A case study reveals how late presentation of this rare, autosomal-recessive disorder, which can involve arthritis-like symptoms, can be mistaken for JIA
Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
By regulating molecules key to osteoclast/osteoblast processes, methotrexate may reduce bone destruction in inflammatory arthritis, osteolysis, especially in combination with adenosine
EULAR 2013: Emerging Imaging Methods in Spondylarthritis Have Advantages and Flaws
New technologies from diffusion-weighted imaging to ultrasonography are being studied and refined, but much is yet to be understood
Rheuminations: New Rules for Rheumatologists
Transparent hospital costs, salary caps for senior hospital executives, and no more faxes top one rheumatologist’s wish list for revised healthcare rules
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
A Journey Begins with the First Step
The ACR Research and Education Foundation (REF) has launched the Action Alliance network, a program that calls on rheumatologists, investigators, and health professionals to join the REF in asking patients and families to be a part of the conversation. The Action Alliance consists of two programs working together: From the Field Speakers Bureau and Patients and Families for Progress.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.